In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles
2002

Amino Acid Prodrugs of Antitumour Benzothiazoles

publication Evidence: moderate

Author Information

Author(s): Bradshaw T D, Chua M-S, Browne H L, Trapani V, Sausville E A, Stevens M F G

Primary Institution: University of Nottingham

Hypothesis

Can amino acid prodrugs of 2-(4-amino-3-methylphenyl)benzothiazoles retain antitumour activity while improving solubility and stability?

Conclusion

Amino acid prodrugs of 2-(4-amino-3-methylphenyl)benzothiazoles are effective and retain their selective antitumour properties.

Supporting Evidence

  • The prodrugs were shown to be rapidly converted back to their active forms in sensitive cancer cells.
  • The study demonstrated that the prodrugs maintained selective antitumour activity against specific cancer cell lines.
  • CYP1A1 activity was selectively induced in sensitive carcinoma cells, supporting the mechanism of action.

Takeaway

Scientists created special versions of a cancer-fighting drug that dissolve better in water and still work well against certain cancer cells.

Methodology

The study involved growth inhibitory assays and metabolism studies using various human cancer cell lines.

Limitations

The prodrugs may have reduced potency compared to their parent compounds in some sensitive cell lines.

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600225

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication